|
Once Weekly Parathyroid Hormone for Osteoporosis Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about Once Weekly Parathyroid Hormone for Osteoporosis conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Once Weekly Parathyroid Hormone for Osteoporosis Clinical research trials and Once Weekly Parathyroid Hormone for Osteoporosis healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as Once Weekly Parathyroid Hormone for Osteoporosis. Once Weekly Parathyroid Hormone for Osteoporosis Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Once Weekly Parathyroid Hormone for Osteoporosis clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their Once Weekly Parathyroid Hormone for Osteoporosis condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "O" Clinical Trials Conditions > Once Weekly Parathyroid Hormone for Osteoporosis  Once Weekly Parathyroid Hormone for Osteoporosis
Once Weekly Parathyroid Hormone for Osteoporosis
For Condition: Osteopenia,Osteoporosis
Status: Not yet recruiting
Sponsor(s): National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) ,
Synopsis: Daily parathyroid hormone (PTH) is approved by the FDA for the treatment of osteoporosis. This study will evaluate the safety and effectiveness of PTH when given once a week.
Details: In osteoporosis, skeletal bone mass and strength are so reduced that fractures occur after only modest levels of mechanical stress that would not harm normal bone. Fractures of the hip, spine, and wrists are most typical, though fractures of the ribs, pelvis, and humerus also occur. Research has shown that hip fractures cause a 10% to 20% increase in mortality, and the cost of all osteoporotic fractures is estimated to be $6.14 billion in health care costs and lost earnings per year. The most common form of osteoporosis is postmenopausal osteoporosis. A reduction in bone mineral density of approximately 1% to 2% per year is observed for the first 3 to 5 years after the onset of menopause, then 0.5% to 1% per year thereafter. PTH was recently approved by the FDA as a daily treatment for osteoporosis. However, PTH must be self-injected, is very expensive, and has been associated with worrisome side effects. The currently approved formulation of daily PTH self-injections is practical for only a small proportion of people with osteoporosis. A once weekly formulation could significantly decrease cost, difficulty of administration, and risks and side effects associated with daily use of PTH. A once weekly injection by a caregiver would also make PTH accessible to populations for whom daily self-injection may not be practical, such as the very elderly or those in assisted living or nursing homes. This study will evaluate the safety and effectiveness of once weekly PTH dosing for women with osteoporosis. Women will be randomized to receive either PTH or placebo. Women will self-administer injections daily for 4 weeks, then once weekly for 48 weeks. All women will receive calcium and vitamin D supplements daily. Women will visit the clinic six times over the course of a year and will provide urine and blood samples at each visit. Bone mineral density will be measured at 6 and 12 months.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Factorial Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 45 Years/70 Years
Genders: Female
Protocol Entry Criteria: Inclusion Criteria - Bone mineral density scan with a T-score between -1 and -2 - Willing to self-administer injections Exclusion Criteria - Medications to treat osteoporosis - Bone fracture since menopause
Total Enrollment: 50
Location and Contact Information:
Overall Study Official:
CliffordRosen, Principal Investigator,
St Joseph Hospital
Bangor, Maine,
United States
Lorii Fowler 207-262-1176
Additional Information:
Study ID Numbers: NIAMS-092; N01-AR-3-2268
Study Start Date:
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00065637
Other Osteopenia Studies:
1. Diagnostic Pilot Study of Dual Energy Absorptiometry in the Detection of Osteopenia or Osteoporosis in Patients With Thalassemia Major
2. Phase II Randomized Study of Alendronate Sodium for Osteopenia in Patients with Gaucher's Disease
3. Bone Loss in Premenopausal Women with Depression
4. Adding Phosphorus to Osteoporosis Drug Treatment
5. Nitroglycerin Ointment for Preventing Bone Loss in Postmenopausal Women
Related Studies:
Other Osteopenia Clinical Trials
Other Maine Clinical Trials
Other Bangor Clinical Trials
Once Weekly Parathyroid Hormone for Osteoporosis
|
|
|
|
|
|
|
|
